Suzhou Baidi Boyuan Biotechnology

Suzhou BodMed (BodMed) is a pioneering Chinese biotechnology company specializing in the development of mucosal RNA medicines. Founded in December 2021 and headquartered in Suzhou, China, the company leverages its proprietary MucoRD® mucosal delivery platform and ETP® tumor immune enhancement design platform to develop non-LNP, non-viral inhaled mRNA therapeutics. Its lead pipeline candidates include BMD003, an inhaled CFTR mRNA freeze-dried formulation for cystic fibrosis, and BMD006, a first-in-class inhaled mRNA tumor-associated antigen dry powder vaccine for advanced lung cancer and solid tumors. BodMed aims to accelerate the clinical translation of RNA therapeutics to improve patient outcomes globally.